Clinical Trial

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-12; most recent amendment 2026-02-16.
Status change: Not Yet Recruiting → Recruiting 2026-01-05
Trial Details
NCT Number NCT07174427
Lead Sponsor Takara Bio Inc.
Conditions Synovial Sarcomas
Enrollment 5 participants
Start Date 2026-01-05
Primary Completion 2032-03 (estimated)
Study Completion 2032-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-18